Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel C Cattran

Showing results (1-10 of 109) with videos related to

Pageof 11
Sort By:
Kidney International|January 12, 2002
Membranous nephropathy: quo vadis?Daniel C Cattran
Seminars in Nephrology|August 19, 2003
Outcomes research in glomerulonephritisDaniel C Cattran
Seminars in Nephrology|April 22, 2003
Cyclosporine in the treatment of idiopathic focal segmental glomerulosclerosisDaniel C Cattran
Advances in Chronic Kidney Disease|July 26, 2011
Historical aspects of proteinuriaDaniel C Cattran
Seminars in Nephrology|July 3, 2003
Mycophenolate mofetil and cyclosporine therapy in membranous nephropathyDaniel C Cattran
Nature Clinical Practice. Nephrology|October 27, 2006
Is valsartan renoprotective in patients with IgA nephropathy?Daniel C Cattran
Journal of the American Society of Nephrology : JASN|May 15, 2007
Is proteinuria reduction by angiotensin-converting enzyme inhibition enough to prove its role in renal protection in IgA nephropathy?Daniel C Cattran
Kidney International|September 17, 2016
Toward quantitating the burden of glomerulonephritis in the United StatesDaniel C Cattran
Clinical Journal of the American Society of Nephrology : CJASN|July 24, 2012
Is long-term prediction in membranous nephropathy (MGN) better than the weatherman's forecast capacity?Daniel C Cattran, Joseph Kim
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 15, 2021
Slowly Unraveling the Mysteries of C3GDaniel C Cattran, Sanjeev Sethi
Pageof 11

Showing results (1-10 of 109) with videos related to

Sort By:
Pageof 11
Kidney International|January 12, 2002
Membranous nephropathy: quo vadis?Daniel C Cattran
Seminars in Nephrology|August 19, 2003
Outcomes research in glomerulonephritisDaniel C Cattran
Seminars in Nephrology|April 22, 2003
Cyclosporine in the treatment of idiopathic focal segmental glomerulosclerosisDaniel C Cattran
Advances in Chronic Kidney Disease|July 26, 2011
Historical aspects of proteinuriaDaniel C Cattran
Seminars in Nephrology|July 3, 2003
Mycophenolate mofetil and cyclosporine therapy in membranous nephropathyDaniel C Cattran
Nature Clinical Practice. Nephrology|October 27, 2006
Is valsartan renoprotective in patients with IgA nephropathy?Daniel C Cattran
Journal of the American Society of Nephrology : JASN|May 15, 2007
Is proteinuria reduction by angiotensin-converting enzyme inhibition enough to prove its role in renal protection in IgA nephropathy?Daniel C Cattran
Kidney International|September 17, 2016
Toward quantitating the burden of glomerulonephritis in the United StatesDaniel C Cattran
Clinical Journal of the American Society of Nephrology : CJASN|July 24, 2012
Is long-term prediction in membranous nephropathy (MGN) better than the weatherman's forecast capacity?Daniel C Cattran, Joseph Kim
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 15, 2021
Slowly Unraveling the Mysteries of C3GDaniel C Cattran, Sanjeev Sethi
Pageof 11